Articles related to DEPRESSION

In this NEJM Double Take episode, experts discuss the critical role of neuroplasticity in depression and examine advanced treatment options for patients who do not respond to traditional therapies. Topics include the efficacy of ECT and TMS, as well as emerging evidence for ketamine, esketamine, and psilocybin.

The FDA-approved Rejoyn app, designed for major depressive disorder, combines therapeutic exercises and emotional regulation training to complement antidepressant therapy, showing significant improvement in clinical trials.

Recent studies indicate that while ketamine and ECT are equally effective for treating MDD, ketamine did not prove non-inferior to ECT for MDEs. Both treatments have distinct side effect profiles that are critical for clinical decision-making.

Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.

Rejoyn represents a significant advancement in the treatment of major depressive disorder, requiring prescription use and integrating brain-training exercises developed by leading mental health experts.

Recent clinical case studies highlight that symptoms such as sudden changes in blood sugar levels and depressive episodes without clear psychological causes may be indicative of early-stage pancreatic cancer.